Onward Medical N.V. (ONWD.BR)

5.80 0.00 (0.00%) 市場開市。 截至 10:23AM CEST。

Onward Medical N.V.

Schimmelt 2
Eindhoven NL-5656
Netherlands

https://www.onwd.com

版塊: Healthcare
行業: Biotechnology
全職員工: 99

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. David L. Marver	CEO & Executive Director	767k	無	1968
Dr. Gregoire Courtine Ph.D.	Chief Scientific Officer & Director	無	無	1975
Mr. Khaled Bahi	Interim Chief Financial Officer	無	無	1966
Mr. Robert W. Odell	Vice President of Operations	無	無	1960
Mr. John Murphy	Chief Technology Officer	無	無	無
Ms. Sarah Moore	Vice President of Global Marketing	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Onward Medical N.V., a medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord. The company engages in developing ARCEX, a transcutaneous system designed to improve upper extremity strength, function, and other symptoms in people with spinal cord injury (SCI); ARCIM, a minimally invasive implantable system to address blood pressure instability and other symptoms in people with SCI; and ARCBCI, which adds an implantable bran-computer interface to the ARCIM to restore thought-driven movement of the upper and lower limbs. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

公司管治

截至 無 止，Onward Medical N.V. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。